Navigation Links
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Date:9/11/2007

PT. RICHMOND, Calif., Sept. 11 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, today announced that Glenn A. Oclassen, President and Chief Executive Officer is scheduled to present at the UBS 2007 Global Life Sciences Conference at the Grand Hyatt, New York, NY, on Tuesday, September 25, 2007 at 4:00 p.m. ET.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. The company's development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron that is being evaluated for the treatment of dopamine associated psychiatric disorders (DAPD). TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder (AUD). For more information, please visit the Company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors - Media

Director of Communications Stephanie Carrington/Jason Rando

(510) 215-3575 (646) 536-7017 ext. 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... Hernandez Insurance Agencies, a northern Virginia ... greater DC region, is inaugurating a “New Leash On Life” charity initiative in ... them to be companions for veterans in need. , The Semper K9 organization ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a ... in east Texas, is launching a regional charity effort to provide publicity assistance ... the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations ...
(Date:8/18/2017)... Saint John, IN (PRWEB) , ... August 18, 2017 , ... ... services to communities in northwest Indiana, is campaigning in support of Campagna Academy in ... Formerly referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a ...
(Date:8/18/2017)... ... , ... The Golseth Agency, a Texas based insurance management and financial planning ... charity campaign organized to provide support to Christina Upchurch and her two children after ... her children returned from out of town to find her husband passed away and ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become ... and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... Israel , Aug. 15, 2017 /PRNewswire/ ... of adult stem cell technologies for neurodegenerative diseases, announced ... 2017. "We are ... Phase 3 trial to investigate NurOwn ® in ... Executive Officer of BrainStorm. "We have agreements with Mass. ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
Breaking Medicine Technology: